摘要
目的探讨2型糖尿病患者纤溶活性变化与胰岛素抵抗之间的关系。方法采用酶联免疫吸附法测定63例2型糖尿病患者(包括无血管并发症组30例和有血管并发症组33例)和25例正常对照者血浆组织型纤溶酶原激活剂(t-PA)、纤溶酶原激活物抑制剂-1(PAI-1)含量,结合临床资料分析其变化趋势及影响因素。结果2型糖尿病患者血浆t-PA含量明显降低(P<0.01),而PAI-1含量明显升高(P<0.01),合并血管病变者,此变化更为显著(均P<0.001)。多元逐步回归分析显示,HOMA模型胰岛素抵抗指数(HOMA-IR)是PAI-1升高的独立危险因素。结论2型糖尿病患者纤溶活性降低,胰岛素抵抗在降低其纤溶活性,并发血管病变中起了重要作用。
Objective To investigate the relationship between changes of fibrinolysis in type 2 diabetes mellitus and insulin resistance. Method The serum levels of tissue-type plasminogen activator (t- PA) and its inhibitor, plasminogen activator inhibitor-1 ( PAI-1 ) in 63 diabetic patients ( including 30 cases without diabetic angiopathies and 33 cases with diabetic angiopathies ) and 25 normal controls were measured by ELISA method. We analyzed the change tendency and influential factors combining the clini- cal datas. Result In type 2 diabetic patients, the plasma t-PA level was significantly lower(P 〈 0.01 ) and PAI-1 was significantly higher (P 〈 0.01 )than normal controls. Those with angiopathies, this change was more obvious ( respectively ,P 〈 0. 001 ). By multiple stepwise regression analysis, HOMA-IR was an independent risk factor of PAI-1. Conclusion In type 2 diabetic patients, the fibrinolysis is impaired. Insuhn resistance appears to play an important role in decreasing fibrinolysis of diabetic patients and inducing angiopathies.
出处
《临床内科杂志》
CAS
2005年第9期589-591,共3页
Journal of Clinical Internal Medicine